SCHEMBL13328636

SCHEMBL13328636

CN(C(=O)OCc1ccccc1)C1(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
SIGMAR1 Q99720 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ABCB1 P08183 1/20 0.34
LMNA P02545 1/20 0.34
HTR2C P28335 1/20 0.34
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20485964 0.85 CYP3A4 (0.35) SMN1; SMN2HTR2CL3MBTL1CYP3A4HTT
SCHEMBL18587843 0.85 SMN1; SMN2 (0.37) ALDH1A1MAPTKMT2ASMN1; SMN2CYP3A4
SCHEMBL13211826 0.80 ALDH1A1 (0.45) RORCALDH1A1MAPTHPGDSIGMAR1
SCHEMBL2913515 0.79 CTSL (0.43) RORCALDH1A1KMT2ASMN1; SMN2LMNA
SCHEMBL5724513 0.77 ALDH1A1 (0.40) ALDH1A1MAPTHPGDSIGMAR1SMN1; SMN2
SCHEMBL16219337 0.77 ALDH1A1 (0.47) RORCALDH1A1MAPTHPGDSIGMAR1
SCHEMBL15079559 0.77 ALDH1A1 (0.47) RORCALDH1A1MAPTHPGDSIGMAR1
SCHEMBL20485949 0.76 SMYD2 (0.36) KMT2ASMN1; SMN2LMNAMAPK1L3MBTL1
SCHEMBL15079558 0.76 ALDH1A1 (0.46) RORCALDH1A1MAPTHPGDSIGMAR1
SCHEMBL3142599 0.76 SMN1; SMN2 (0.42) ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723319-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2010-05-25 US disclosed
US-20100004440-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2010-01-07 US disclosed
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 US disclosed
US-7157448-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2007-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004440-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same PNP, ITPA, MTAP RORC 2145/4885ALDH1A1 2937/4885MAPT 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.